TY - JOUR
T1 - Antibody-Based Therapeutics for the Treatment of Renal Cell Carcinoma
T2 - Challenges and Opportunities
AU - Mahmoud, Ahmed M.
AU - Nabavizadeh, Reza
AU - Rodrigues Pessoa, Rodrigo
AU - Garg, Ishita
AU - Orme, Jacob
AU - Costello, Brian A.
AU - Cheville, John
AU - Lucien, Fabrice
N1 - Publisher Copyright:
© The Author(s) 2023. Published by Oxford University Press.
PY - 2023/4/6
Y1 - 2023/4/6
N2 - Renal cell carcinoma (RCC) is among the top 10 most common cancers in both men and women with an estimated 75 000 cases each year in the US. Over the last decade, the therapeutic landscape for patients with metastatic RCC has significantly evolved, with immunotherapy emerging as the new front-line therapy. Despite significant improvement in toxicity profile and survival outcomes, key concerns such as patient selection, treatment sequencing, and intrinsic and acquired resistance remain unresolved. Emerging options such as antibody-based therapeutics (eg, anti-CD70, anti-CA9, and anti-ENPP3) are being explored in clinical trials for patients with cancer resistant or refractory to current immunotherapies. Despite positive results for hematological cancers, breast cancer, and more recently bladder cancer, most antibody-based therapies failed to improve the outcomes in patients with advanced RCC. This underscores the need to understand the underlying causes of failed responses to this treatment class, which will ultimately support the rational design of more effective and tolerable treatments. In this review, we summarize the evolving landscape of RCC therapeutics and describe recent clinical trials with emerging antibody-based therapeutics. We also describe the challenges that need to be overcome for the successful creation of therapeutic antibodies for treating RCC.
AB - Renal cell carcinoma (RCC) is among the top 10 most common cancers in both men and women with an estimated 75 000 cases each year in the US. Over the last decade, the therapeutic landscape for patients with metastatic RCC has significantly evolved, with immunotherapy emerging as the new front-line therapy. Despite significant improvement in toxicity profile and survival outcomes, key concerns such as patient selection, treatment sequencing, and intrinsic and acquired resistance remain unresolved. Emerging options such as antibody-based therapeutics (eg, anti-CD70, anti-CA9, and anti-ENPP3) are being explored in clinical trials for patients with cancer resistant or refractory to current immunotherapies. Despite positive results for hematological cancers, breast cancer, and more recently bladder cancer, most antibody-based therapies failed to improve the outcomes in patients with advanced RCC. This underscores the need to understand the underlying causes of failed responses to this treatment class, which will ultimately support the rational design of more effective and tolerable treatments. In this review, we summarize the evolving landscape of RCC therapeutics and describe recent clinical trials with emerging antibody-based therapeutics. We also describe the challenges that need to be overcome for the successful creation of therapeutic antibodies for treating RCC.
KW - antibody-based therapies
KW - clinical trials
KW - emerging drugs
KW - immunotherapy
KW - metastatic RCC
KW - renal cell carcinoma
UR - http://www.scopus.com/inward/record.url?scp=85152172612&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85152172612&partnerID=8YFLogxK
U2 - 10.1093/oncolo/oyac263
DO - 10.1093/oncolo/oyac263
M3 - Review article
C2 - 36745503
AN - SCOPUS:85152172612
SN - 1083-7159
VL - 28
SP - 297
EP - 308
JO - The oncologist
JF - The oncologist
IS - 4
ER -